Polymorphism of cytochrome P450 2B6 and prostate cancer risk: A significant association in a Japanese population

International Journal of Urology

Volumn 16, Issue 4, 2009, Pages 364-368

  Kurosaki, Takayuki ^a   Suzuki, Motofumi ^a   Enomoto, Yutaka ^a   Arai, Tomio ^b   Sawabe, Motoji ^b   Hosoi, Takayuki ^c   Homma, Yukio ^a   Kitamura, Tadaichi ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Metropolitan Institute of Gerontology   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^d Asoka Hospital   (Japan)

Author keywords

CYP2B6; Prostate cancer; Single nucleotide polymorphism; TaqMan assay; Testosterone

Indexed keywords

ARGININE; CYTOCHROME P450 2B6; LYSINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 64549163699     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02263.x     Document Type: Article

References (30)

1. Ajiki W, Tsukuma H, Oshima A. Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn. J. Clin. Oncol. 2004 34 : 352 6.
2. Isaacs JT. Role of androgens in prostatic cancer. Vitam. Horm. 1994 49 : 433 502.
3. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002 52 : 213 35.
4. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J. Cell. Biochem. 2006 99 : 362 72.
5. Ross JS. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test. Adv. Anat. Pathol. 2007 14 : 353 7.
6. Jacob RM, Johnstone EC, Neville MJ et al. Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin. Chem. 2004 50 : 1372 7.
7. 3 : 424 36.
8. Isaacs JT, McDermott IR, Coffey DS. The identification and characterization of a new C19O3 steroid metabolite in the rat ventral prostate: 5 alpha-androstane-3 beta, 6 alpha, 17 beta-triol. Steroids 1979 33 : 639 57.
9. Isaacs JT, McDermott IR, Coffey DS. Characterization of two new enzymatic activities of the rat ventral prostate: 5 alpha-androstane-3 beta, 17 beta-diol 6 alpha-hydroxylase and 5 alpha-androstane-3 beta, 17 beta-diol 7 alpha-hydroxylase. Steroids 1979 33 : 675 92.
10. Sundin M, Warner M, Haaparanta T et al. Isolation and catalytic activity of cytochrome P-450 from ventral prostate of control rats. J. Biol. Chem. 1987 262 : 12293 7.
11. Parkinson A, Mudra DR, Johnson C et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 2004 199 : 193 209.
12. Kittles RA, Chen W, Panguluri RK et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum. Genet. 2002 110 : 553 60.
13. Antona CR, Sundberg MI. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006 25 : 1679 91.
14. Lang TA, Klein K, Fisher J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001 11 : 399 415.
15. Xie HJ, Yasar U, Lundgren S et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics. J. 2003 3 : 53 61.
16. Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004 14 : 225 38.
17. Sabin LH, Wittekind C. (eds). TNM Classification of Malignant Tumors, 6th edn. Wiley-Liss, New York, 2002.
18. Suzuki M, Kurosaki T, Arai T et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men. Int. J. Urol. 2007 14 : 800 4.
19. Sawabe M, Arai T, Kasahara I et al. Developments of geriatric autopsy database and Internet-based database of Japanese single nucleotide polymorphisms for geriatric research (JG-SNP). Mech. Ageing Dev. 2004 125 : 547 52.
20. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet. Anal. 1999 14 : 143 9.
21. Massengill JC, Sun L, Moul JW et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 2003 169 : 1670 5.
22. Schatzl G, Madersbacher S, Thurridl T et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001 47 : 52 8.
23. Isom-Batz G, Bianco FJ Jr., Kattan MW et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J. Urol. 2005 173 : 1935 7.
24. Yamamoto S, Yonese J, Kawakami S et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur. Urol. 2007 52 : 696 701.
25. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003 349 : 215 24.
26. Scardino PT. The prevention of prostate cancer - the dilemma continues. N. Engl. J. Med. 2003 349 : 297 9.
27. Morgentaler A, Bruning CO 3rd., DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996 276 : 1904 6.
28. Heracek J, Hampl R, Hill M et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 2007 72 : 375 80.
29. Neslund-Dudas C, Bock CH, Monaghan K et al. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 2007 67 : 1654 63.
30. Söderström T, Wadelius M, Andersson SO et al. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002 12 : 307 12.